Huaren Pharmaceutical Co Ltd (300110) - Net Assets
Based on the latest financial reports, Huaren Pharmaceutical Co Ltd (300110) has net assets worth CN¥1.43 Billion CNY (≈ $208.65 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.40 Billion ≈ $497.06 Million USD) and total liabilities (CN¥1.97 Billion ≈ $288.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Huaren Pharmaceutical Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.43 Billion |
| % of Total Assets | 41.98% |
| Annual Growth Rate | 12.53% |
| 5-Year Change | -41.02% |
| 10-Year Change | -4.59% |
| Growth Volatility | 60.78 |
Huaren Pharmaceutical Co Ltd - Net Assets Trend (2007–2024)
This chart illustrates how Huaren Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Huaren Pharmaceutical Co Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Huaren Pharmaceutical Co Ltd (2007–2024)
The table below shows the annual net assets of Huaren Pharmaceutical Co Ltd from 2007 to 2024. For live valuation and market cap data, see 300110 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.37 Billion ≈ $201.05 Million |
-50.33% |
| 2023-12-31 | CN¥2.77 Billion ≈ $404.75 Million |
+6.39% |
| 2022-12-31 | CN¥2.60 Billion ≈ $380.43 Million |
+6.40% |
| 2021-12-31 | CN¥2.44 Billion ≈ $357.55 Million |
+4.89% |
| 2020-12-31 | CN¥2.33 Billion ≈ $340.88 Million |
+3.60% |
| 2019-12-31 | CN¥2.25 Billion ≈ $329.02 Million |
-0.21% |
| 2018-12-31 | CN¥2.25 Billion ≈ $329.72 Million |
+45.54% |
| 2017-12-31 | CN¥1.55 Billion ≈ $226.55 Million |
+1.46% |
| 2016-12-31 | CN¥1.53 Billion ≈ $223.29 Million |
+5.97% |
| 2015-12-31 | CN¥1.44 Billion ≈ $210.71 Million |
-2.69% |
| 2014-12-31 | CN¥1.48 Billion ≈ $216.53 Million |
+1.40% |
| 2013-12-31 | CN¥1.46 Billion ≈ $213.55 Million |
+8.97% |
| 2012-12-31 | CN¥1.34 Billion ≈ $195.97 Million |
+12.38% |
| 2011-12-31 | CN¥1.19 Billion ≈ $174.38 Million |
+7.93% |
| 2010-12-31 | CN¥1.10 Billion ≈ $161.57 Million |
+251.86% |
| 2009-12-31 | CN¥313.80 Million ≈ $45.92 Million |
+41.97% |
| 2008-12-31 | CN¥221.03 Million ≈ $32.34 Million |
+19.69% |
| 2007-12-31 | CN¥184.68 Million ≈ $27.02 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Huaren Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2379.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥1.18 Billion | 90.88% |
| Other Components | CN¥618.57 Million | 47.55% |
| Total Equity | CN¥1.30 Billion | 100.00% |
Huaren Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Huaren Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sage Therapeutics Inc
NASDAQ:SAGE
|
$544.94 Million |
|
MiMedx Group Inc
NASDAQ:MDXG
|
$545.02 Million |
|
AB S.A.
WAR:ABE
|
$545.03 Million |
|
Flushing Financial Corporation
NASDAQ:FFIC
|
$545.18 Million |
|
Hangzhou Seck Intelligent Tech Co
SHE:300897
|
$544.56 Million |
|
C.E. Info Systems Limited
NSE:MAPMYINDIA
|
$544.27 Million |
|
Ningbo Fangzheng Automobile Mould Co.Ltd.
SHE:300998
|
$544.16 Million |
|
Tibet Aim Pharm Inc
SHE:002826
|
$544.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Huaren Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,694,091,730 to 1,300,786,289, a change of -1,393,305,441 (-51.7%).
- Net loss of 1,368,478,968 reduced equity.
- Dividend payments of 78,895,504 reduced retained earnings.
- Other factors increased equity by 54,069,031.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-1.37 Billion | -105.2% |
| Dividends Paid | CN¥78.90 Million | -6.07% |
| Other Changes | CN¥54.07 Million | +4.16% |
| Total Change | CN¥- | -51.72% |
Book Value vs Market Value Analysis
This analysis compares Huaren Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.86x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 13.08x to 2.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.24 | CN¥3.15 | x |
| 2008-12-31 | CN¥0.29 | CN¥3.15 | x |
| 2009-12-31 | CN¥0.40 | CN¥3.15 | x |
| 2010-12-31 | CN¥1.20 | CN¥3.15 | x |
| 2011-12-31 | CN¥1.08 | CN¥3.15 | x |
| 2012-12-31 | CN¥1.13 | CN¥3.15 | x |
| 2013-12-31 | CN¥1.32 | CN¥3.15 | x |
| 2014-12-31 | CN¥1.22 | CN¥3.15 | x |
| 2015-12-31 | CN¥1.25 | CN¥3.15 | x |
| 2016-12-31 | CN¥1.21 | CN¥3.15 | x |
| 2017-12-31 | CN¥1.51 | CN¥3.15 | x |
| 2018-12-31 | CN¥1.89 | CN¥3.15 | x |
| 2019-12-31 | CN¥1.84 | CN¥3.15 | x |
| 2020-12-31 | CN¥1.91 | CN¥3.15 | x |
| 2021-12-31 | CN¥2.01 | CN¥3.15 | x |
| 2022-12-31 | CN¥2.14 | CN¥3.15 | x |
| 2023-12-31 | CN¥2.28 | CN¥3.15 | x |
| 2024-12-31 | CN¥1.10 | CN¥3.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Huaren Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -105.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -101.13%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 2.64x
- Recent ROE (-105.20%) is below the historical average (1.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 18.49% | 21.19% | 0.44x | 1.96x | CN¥15.67 Million |
| 2008 | 21.01% | 22.37% | 0.41x | 2.30x | CN¥24.33 Million |
| 2009 | 19.36% | 21.06% | 0.45x | 2.03x | CN¥29.39 Million |
| 2010 | 6.91% | 22.56% | 0.29x | 1.04x | CN¥-34.10 Million |
| 2011 | 7.35% | 21.60% | 0.32x | 1.05x | CN¥-31.61 Million |
| 2012 | 7.51% | 17.19% | 0.31x | 1.39x | CN¥-32.11 Million |
| 2013 | 8.33% | 14.01% | 0.37x | 1.62x | CN¥-24.41 Million |
| 2014 | 3.79% | 6.13% | 0.35x | 1.77x | CN¥-91.82 Million |
| 2015 | 1.59% | 2.07% | 0.40x | 1.91x | CN¥-121.14 Million |
| 2016 | 1.63% | 1.92% | 0.46x | 1.86x | CN¥-122.52 Million |
| 2017 | 2.53% | 2.86% | 0.45x | 1.94x | CN¥-111.01 Million |
| 2018 | 1.78% | 2.80% | 0.44x | 1.44x | CN¥-179.28 Million |
| 2019 | 1.93% | 2.88% | 0.54x | 1.25x | CN¥-175.52 Million |
| 2020 | 4.19% | 7.19% | 0.39x | 1.51x | CN¥-131.24 Million |
| 2021 | 5.50% | 8.35% | 0.28x | 2.38x | CN¥-106.73 Million |
| 2022 | 7.14% | 11.16% | 0.31x | 2.04x | CN¥-72.31 Million |
| 2023 | 6.98% | 11.49% | 0.32x | 1.92x | CN¥-81.35 Million |
| 2024 | -105.20% | -101.13% | 0.39x | 2.64x | CN¥-1.50 Billion |
Industry Comparison
This section compares Huaren Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Huaren Pharmaceutical Co Ltd (300110) | CN¥1.43 Billion | 18.49% | 1.38x | $544.93 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Huaren Pharmaceutical Co Ltd
Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therape… Read more